The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) Study: A Multicenter Study

• Published in: Pharmacotherapy 2011-08, Vol.31 (8), p.767-775
• Main Authors: Yost, Raymond J., Cappelletty, Diane M.
• Format: Article
• Language: English
• Subjects: Aged; Anti-Bacterial Agents - administration & dosage; Anti-Bacterial Agents - therapeutic use; Biological and medical sciences; Cohort Studies; extended infusion; Female; Gram-Negative Bacterial Infections - drug therapy; Gram-Negative Bacterial Infections - microbiology; Gram-Negative Bacterial Infections - mortality; gram-negative infection; Hospital Mortality; Humans; Infusions, Intravenous; Length of Stay; Male; Medical sciences; Middle Aged; Multivariate Analysis; Penicillanic Acid - administration & dosage; Penicillanic Acid - analogs & derivatives; Penicillanic Acid - therapeutic use; Pharmacology. Drug treatments; Piperacillin - administration & dosage; Piperacillin - therapeutic use; piperacillin-tazobactam; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome
• ISSN: 0277-0008; 1875-9114
• DOI: 10.1592/phco.31.8.767

Study Objective. To compare the effectiveness of extended‐infusion piperacillin‐tazobactam with that of similar‐spectrum, nonextended‐infusion β‐lactam antibiotics in the treatment of gram‐negative infections. Design. Multicenter, retrospective medical record review. Setting. Fourteen hospitals throughout the United States. Patients. A total of 359 adults treated for gram‐negative infections between January 1, 2007, and February 28, 2010, with either 4‐hour extended‐infusion piperacillin‐tazobactam (186 patients) or nonextended‐infusion comparator antibiotics (173 patients), which consisted of cefepime, ceftazidime, imipenem‐cilastatin, meropenem, doripenem, or piperacillin‐tazobactam. Measurements and Main Results. Deidentified data were collected on demographics, renal function, Acute Physiology and Chronic Health Evaluation II score, chronic health conditions, source of infection and type of organism, intensive care unit (ICU) length of stay, total length of stay, type and duration of antimicrobial therapy, and in‐hospital mortality. The primary outcome was mortality rate of the patients receiving extended‐infusion piperacillin‐tazobactam versus those receiving nonextended‐infusion comparator antibiotics. Secondary outcomes were hospital length of stay, ICU length of stay, and total duration of antibiotic therapy. Baseline characteristics were similar between groups, except a significantly lower proportion of patients in the extended‐infusion group were treated with a concomitant intravenous aminoglycoside (5.9% vs 16.2%, p